{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:55:08Z","timestamp":1770972908829,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Clinigen Specialty Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.ijantimicag.2014.12.006","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T00:36:49Z","timestamp":1419381409000},"page":"213-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["The clinical positioning of telavancin in Europe"],"prefix":"10.1016","volume":"45","author":[{"given":"Robert","family":"Masterton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cornaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Courvalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut M.","family":"Lode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Rello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0380","series-title":"EPAR summary for the public. Vibativ, telavancin","author":"European Medicines Agency","year":"2011"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0385","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7164\/antibiotics.57.326","article-title":"Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424)","volume":"57","author":"Leadbetter","year":"2004","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0390","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/dkl235","article-title":"Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus","volume":"58","author":"Leuthner","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0395","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0400","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/AAC.48.8.3043-3050.2004","article-title":"Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria","volume":"48","author":"Hegde","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0405","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.49.8.3163-3165.2005","article-title":"Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus","volume":"49","author":"Madrigal","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0410","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/AAC.49.1.195-201.2005","article-title":"Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects","volume":"49","author":"Shaw","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0415","series-title":"14th European congress of clinical microbiology and infectious diseases (ECCMID)","article-title":"Single dose pharmacokinetics (PK) of telavancin in healthy elderly subjects","author":"Duchin","year":"2004"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0420","series-title":"46th interscience conference on antimicrobial agents and chemotherapy (ICAAC)","article-title":"Pharmacokinetics of intravenous telavancin in subjects with hepatic impairment","author":"Wong","year":"2006"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0425","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/429914","article-title":"Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria","volume":"40","author":"Stryjewski","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0430","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/AAC.50.3.862-867.2006","article-title":"Telavancin versus standard therapy for the treatment of complicated skin and skin structure infections caused by Gram positive bacteria: FAST 2 Study","volume":"3","author":"Stryjewski","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0435","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0440","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens","volume":"52","author":"Rubinstein","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0445","series-title":"Questions and answers on shortcomings in quality assurance at Ben Venue Laboratories. Interim recommendations for centrally authorised medicines","author":"European Medicines Agency","year":"2011"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0450","series-title":"Vibativ. Procedural steps taken and scientific information after the authorisation","author":"European Medicines Agency","year":"2014"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0455","series-title":"Clinigen Group reports pan European lifting of marketing authorization suspension for VIBATIV\u00ae (telavancin)","author":"London Stock Exchange","year":"2014"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0460","series-title":"Evidence summary: new medicine. Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0465","series-title":"FDA approved drug products. Drug details: Vibativ","author":"US Food and Drug Administration","year":"2009"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0470","unstructured":"Canadian Antimicrobial Resistance Alliance. Telavancin. \u3008http:\/\/www.can-r.com\/mediaResources\/About%20Telavancin.pdf\u3009 [accessed 6 May 2014]."},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0475","series-title":"FDA news release: FDA approves Vibativ for hospitalized patients with bacterial pneumonia","author":"US Food and Drug Administration","year":"2013"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0480","unstructured":"Telavancin summary of product characteristics (EU). First issued 2 September 2011. \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001240\/WC500115364.pdf\u3009 [accessed 8 May 2014]."},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0485","series-title":"News release. Astellas announces the withdrawal of EU MAA application for telavancin for complicated skin and soft tissue infections","author":"Astellas Pharma Inc.","year":"2008"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0490","unstructured":"Telavancin prescribing information (US). Revised June 2013. \u3008http:\/\/www.vibativ.com\/docs\/VIBATIV_PI_Final.pdf\u3009 [accessed 8 May 2014]"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0495","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/dkh156","article-title":"Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria","volume":"53","author":"King","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0500","series-title":"46th interscience conference on antimicrobial agents and chemotherapy (ICAAC)","article-title":"Baseline antistaphylococcal profile of telavancin: results of the 2004\u20132005 U.S. Surveillance Initiative","author":"Draghi","year":"2006"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0505","series-title":"46th interscience conference on antimicrobial agents and chemotherapy (ICAAC)","article-title":"In vitro activity of telavancin against enterococci: results from the 2004\u20132005 U.S. Surveillance Initiative","author":"Draghi","year":"2006"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0510","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/jac\/dkm211","article-title":"Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus","volume":"60","author":"Saravolatz","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0515","series-title":"46th interscience conference on antimicrobial agents and chemotherapy (ICAAC)","article-title":"Baseline profile of telavancin activity against streptococci: results of the 2004\u20132005 U.S. Surveillance Initiative","author":"Thornsberry","year":"2006"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0520","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1128\/AAC.48.6.2149-2152.2004","article-title":"In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic Gram-positive species and Corynebacterium spp.","volume":"48","author":"Goldstein","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0525","series-title":"45th interscience conference on antimicrobial agents and chemotherapy (ICAAC)","article-title":"In vitro activity of telavancin and six comparator agents against 460 anaerobic bacteria","author":"Finegold","year":"2005"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0530","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0535","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.01710-08","article-title":"Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II","volume":"53","author":"Lunde","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0540","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1592\/phco.28.4.458","article-title":"Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious Gram-positive infections","volume":"28","author":"Leonard","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0545","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1128\/AAC.47.11.3602-3604.2003","article-title":"In vitro activity of TD-6424 against Staphylococcus aureus","volume":"47","author":"Pace","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0550","first-page":"25","article-title":"Telavancin in the treatment of invasive Gram-positive infections","volume":"4","author":"Keynan","year":"2012","journal-title":"Clin Audit"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0555","first-page":"87","article-title":"Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections","volume":"4","author":"Jafari Saraf","year":"2011","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0560","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1128\/AAC.01470-06","article-title":"The pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus in the presence of human albumin or serum, and in an in vitro kinetic model","volume":"51","author":"Odenholt","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0565","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1128\/AAC.00742-09","article-title":"Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies","volume":"53","author":"Kosowska-Shick","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0570","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/jac\/dkn288","article-title":"Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model","volume":"62","author":"Lubenko","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0575","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1128\/AAC.00231-09","article-title":"Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia","volume":"53","author":"Rubino","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0580","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/AAC.01513-07","article-title":"Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing","volume":"52","author":"Arhin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0585","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijantimicag.2012.10.016","article-title":"In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci","volume":"41","author":"Hope","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0590","series-title":"Highlights of prescribing information","author":"US Food and Drug Administration (FDA)","year":"2014"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0595","series-title":"VIBATIV (telavancin hydrochloride) injection, powder, lyophilized, for solution (Theravance, Inc.). Highlights of prescribing information","author":"US National Library of Medicine","year":"2014"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0600","series-title":"24th European congress of clinical microbiology and infectious diseases (ECCMID)","article-title":"Telavancin activity against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011\u20132013) when using a revised susceptibility testing method","author":"Mendes","year":"2014"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0605","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1128\/AAC.00908-08","article-title":"In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates","volume":"53","author":"Finegold","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0610","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/jac\/dkq335","article-title":"Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia","volume":"65","author":"Pfaller","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0615","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1128\/AAC.00100-07","article-title":"In vitro activity of telavancin against Gram-positive clinical isolates recently obtained in Europe","volume":"51","author":"Jansen","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0620","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1128\/AAC.00011-12","article-title":"Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents","volume":"56","author":"Mendes","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0625","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.00301-10","article-title":"In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates","volume":"54","author":"Mendes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0630","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/cid\/cis492","article-title":"In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates","volume":"55","author":"Saravolatz","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0635","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jac\/dki198","article-title":"Telavancin: in vitro activity against staphylococci in a biofilm model","volume":"56","author":"Gander","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0640","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1128\/AAC.01642-08","article-title":"In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains","volume":"53","author":"LaPlante","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0645","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s10096-013-1883-z","article-title":"Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models","volume":"32","author":"Smith","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0650","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0655","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0149-2918(03)80118-2","article-title":"Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia","volume":"25","author":"Wunderink","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0660","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0012-3692(15)33412-7","article-title":"Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0665","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0670","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkt490","article-title":"Analysis of phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure","volume":"69","author":"Torres","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0675","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s40265-013-0144-x","article-title":"Telavancin: a review of its use in patients with nosocomial pneumonia","volume":"73","author":"Scott","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0680","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.01750-09","article-title":"Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers","volume":"54","author":"Shaw","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0685","doi-asserted-by":"crossref","first-page":"e41870","DOI":"10.1371\/journal.pone.0041870","article-title":"Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis","volume":"7","author":"Polyzos","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0690","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2217\/fmb.14.4","article-title":"The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia","volume":"9","author":"Barriere","year":"2014","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0695","unstructured":"Clinigen Specialty Pharmaceuticals. Direct Healthcare Professional Communication on the launch of Vibativ\u00ae (telavancin): recommendations for use and important risks (nephrotoxicity, QTc prolongation, reproductive toxicity and off-label use). \u3008http:\/\/www.mhra.gov.uk\/home\/groups\/comms-ic\/documents\/drugsafetymessage\/con428392.pdf\u3009 [accessed 30 November 2014]."},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0700","first-page":"127","article-title":"Telavancin (Vibativ), a new option for the treatment of Gram-positive infections","volume":"36","author":"Plotkin","year":"2011","journal-title":"P T"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0705","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/2047-783X-15-12-507","article-title":"Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? Comparison of pharmacology and clinical efficacy","volume":"15","author":"Pletz","year":"2010","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0710","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1086\/518452","article-title":"Counterpoint: vancomycin and Staphylococcus aureus\u2014an antibiotic enters obsolescence","volume":"44","author":"Deresinski","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0715","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0720","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1345\/aph.1R420","article-title":"Review of continuous-infusion vancomycin","volume":"47","author":"DiMondi","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0725","series-title":"Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), 2012","article-title":"Antimicrobial resistance surveillance in Europe","author":"European Centre for Disease Prevention and Control","year":"2013"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0730","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/cid\/cit614","article-title":"Methicillin-resistant Staphylococcus aureus therapy: past, present, and future","volume":"58","author":"Rodvold","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0735","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1378\/chest.07-2020","article-title":"Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization","volume":"133","author":"Vidaur","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0740","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3109\/00365548.2012.704151","article-title":"Co-infection by two linezolid-resistant coagulase-negative staphylococci with two different resistance determinants","volume":"44","author":"Mazzariol","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0745","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10096-011-1343-6","article-title":"Outbreak of linezolid-resistant Staphylococcus haemolyticus in an Italian intensive care unit","volume":"31","author":"Mazzariol","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.12.006_bib0750","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3201\/eid2005.130783","article-title":"Linezolid-resistant Staphylococcus epidermidis, Portugal, 2012","volume":"20","author":"Barros","year":"2014","journal-title":"Emerg Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914003847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914003847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:31:19Z","timestamp":1760376679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857914003847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0924857914003847"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.12.006","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical positioning of telavancin in Europe","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}